復鋭醫療(01696.HK):復星醫藥擬通過受讓增持公司21.93%的股份 持股增至74.76%
格隆匯9月30日丨復星醫藥(600196.SH)公佈,2019年9月30日,公司控股子公司Ample Up Limited(即能悦有限公司,“Ample Up”)與關聯方Magnificent View簽訂《Share Purchase Agreement》,Ample Up擬以4.02港元/股受讓Magnificent View持有的復鋭醫療科技(01696.HK)9697.6萬股股份,約佔復鋭醫療科技截至公告日已發行股份總數的21.93%,交易對價約3.90億港元。
此次交易完成後,集團對復鋭醫療科技的持股比例將由52.82%增至74.76%,復鋭醫療科技仍為公司的控股子公司。作為集團醫療器械研發和製造重要平台之一,此次交易將有利於集團更好地支持復鋭醫療科技在醫療技術領域的佈局和發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.